scispace - formally typeset
Patent

Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-α function

TLDR
In this paper, a method of treating an animal suffering from insulin resistance in obesity linked Type II diabetes mellitus is disclosed, which includes providing a therapeutic agent that includes an antagonist to TNF-α function in a pharmaceutically acceptable carrier substance and administering a pharmacologically effective amount of the therapeutic agent to the animal.
Abstract
An induction of TNF-α mRNA expression has been observed in adipose tissue from four different insulin resistant rodent models of obesity and diabetes. TNF-α protein was also elevated locally and systemically. Neutralization of TNF-α in obese fa/fa rats caused a significant increase in the peripheral uptake of glucose in response to insulin. A method of treating an animal suffering from insulin resistance in obesity linked Type II diabetes mellitus is disclosed. The method includes providing a therapeutic agent that includes an antagonist to TNF-α function in a pharmaceutically acceptable carrier substance and administering a pharmacologically effective amount of the therapeutic agent to the animal.

read more

Citations
More filters
Patent

Human antibodies that bind human TNFalpha

TL;DR: In this paper, recombinant human antibodies that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed, which are useful for detecting and inhibiting human TNFα activity.
Patent

Anti-TNF antibodies and peptides of human tumor necrosis factor

TL;DR: In this paper, an anti-TNF peptide is selected from a soluble portion of a TNF receptor, an antiTNF antibody or structural analog thereof, and methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided.
Patent

Tumour necrosis factor binding ligands

TL;DR: In this article, the authors proposed a method to modify the biological activity of TNF by binding a ligand to a human tumour necrosis factor alpha (TNF) protein.
Patent

Anti-tnf antibodies, compositions, methods and uses

TL;DR: In this article, the present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof.
Patent

Formulation of human antibodies for treating tnf-alpha associated disorders

TL;DR: In this article, a liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability, which is similar to our formulation.
References
More filters
Journal ArticleDOI

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

TL;DR: A role for TNF-alpha in obesity and particularly in the insulin resistance and diabetes that often accompany obesity is indicated.
Journal ArticleDOI

Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate.

TL;DR: It is postulated that the aduls syndrome represents a multifacted nueroendocrine disturbance arising from the disruption of developing nueral centers concered in the mediation of endocrine function.
Journal ArticleDOI

The biology of cachectin/TNF--a primary mediator of the host response

TL;DR: A limited number of cytokines are capable of orches­ trating disease states that scarcely resemble one another; among them, endotoxic shock, graft-vs-host disease, cerebral malaria, and cancer cachexia.
Journal ArticleDOI

Cachectin and tumour necrosis factor as two sides of the same biological coin

TL;DR: The identity of cachectin and tumour necrosis factor has led to a new view of its therapeutic potential and its ability to induce wasting as well as a lethal state of shock.